|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A prophylactic thyroidectomy was performed in three cases (5.4%) without clinical signs of thyroid tumor with diagnosed RET gene mutation.
|
24794415 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
All fusions identified were between RET and KIF5B genes, and no RET fusions to CCDC6 or NCOA4 genes, characteristic for thyroid cancer, were identified in the irradiated lung cells.
|
24346100 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Somatic point mutations and translocations of the REarranged during Transfection (RET) proto-oncogene are frequently found in thyroid cancer.
|
25330015 |
2014 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Central role of RET in thyroid cancer.
|
24296167 |
2013 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET, a transmembrane receptor tyrosine kinase and a receptor for the glial cell-derived neurotrophic factor family ligands, was one of the first oncogenes to be identified, and has been shown to be an oncogene in thyroid cancer and pheochromocytoma.
|
22751117 |
2013 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Exons 10, 11, 13, and 16 were sequenced in all, and all exons of RET in 43 of the subjects, including those with thyroid cancer, RET mutations, suspicious clinical findings, and familial or long-segment disease.
|
23744765 |
2013 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
|
23526464 |
2013 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
CCDC6 was originally identified in chimeric genes as caused by chromosomal translocation involving the RET protooncogene in some thyroid tumors.
|
23145146 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Nevertheless, an extensive molecular analysis that included all codons was prompted by the diagnosis of thyroid neoplasm in a patient's sister, and identified the rare intracellular RET p.Ser891Ala mutation.
|
23295303 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
We did a comprehensive screen for 548 known and putative fusion genes in 27 samples of thyroid tumors and three positive controls-one thyroid cancer cell line (TPC-1) and two PTCs with known CCDC6-RET (alias RET/PTC1) fusion gene, using this microarray.
|
22961909 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Germline RET proto-oncogene mutations are the genetic causes of multiple endocrine neoplasia type 2 and a strong genotype-phenotype correlation exists, particularly between a specific RET codon mutation and the (a) age-related onset and (b) thyroid tumor progression, from C-cell hyperplasia to medullary thyroid carcinoma and, ultimately, to nodal metastases.
|
22584703 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using human thyroid cancer-derived cell lines [harboring rearranged during transfection (RET)/PTC, v-RAF murine sarcoma viral oncogene homolog B (BRAF), or rat sarcoma virus oncogene (RAS) alterations], we determined that IL-6/gp130/JAK signaling is responsible for STAT3 activation.
|
22891351 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
The rearranged during transfection/papillary thyroid carcinoma (RET/PTC) tyrosine kinase is an oncogene implicated in the tumorigenesis of thyroid cancer.
|
21947652 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.
|
23056499 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
Further, we found that the frequency of FRET-SE between four pairs of genes that form rearrangements in thyroid cancer was 5% for RET and CCDC6, 4% for RET and NCOA4, 2% for BRAF and AKAP9, and 2% for NTRK1 and TPR.
|
22887574 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
|
22025146 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
|
22025146 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.
|
23056499 |
2012 |
|
Thyroid Neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
|
21470995 |
2011 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Mutations of RET are associated to a subset of colorectal cancer and are commonly found in hereditary and sporadic thyroid cancer.
|
21110809 |
2011 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We tested the effects of a highly selective B-Raf(V600E) inhibitor, PLX4720, on proliferation, migration, and invasion both in human thyroid cancer cell lines (8505c(B-RafV600E) and TPC-1(RET/PTC-1 and wild-type B-Raf)) and in primary human normal thyroid (NT) follicular cells engineered with or without B-Raf(V600E).
|
21355020 |
2011 |
|
Thyroid Neoplasm
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
Targeted therapies for thyroid tumors.
|
21455200 |
2011 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells.
|
21470995 |
2011 |
|
Thyroid Neoplasm
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Common mutations found in thyroid cancer are point mutation of the BRAF and RAS genes as well as RET/PTC and PAX8/PPARγ chromosomal rearrangements.
|
21878896 |
2011 |
|
Thyroid Neoplasm
|
0.700 |
Biomarker
|
disease |
BEFREE |
RET/PTC is a characteristic genetic alteration frequently found in radiation-induced thyroid cancer in human populations.
|
22136268 |
2011 |